Baixar PDF
Artigo anterior
Voltar à página
Artigo seguinte
If you have problems to see the content please click here
Outros usuários também visualizaram estes artigos
EFFICACY AND SAFETY OF ELRANATAMAB IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND PRIOR B-CELL MATURATION ANTIGEN¿DIRECTED THERAPIES: A POOLED ANALYSIS FROM MAGNETISMM STUDIES
A Nooka; A Lesokhin; M Mohty; R Niesvizky; C Maisel; B Arnulf; S Larson; A Varshavsky-Yanovsky; X Leleu; L Karlin; D Vesole; N Bahlis; CF Larrea; N Raje; E Leip; U Conte; M Elmeliegy; A Viqueira; V Blunk; S Manier;
Hematol Transfus Cell Ther. 2023;45 Supl 4:S405
EFFICACY AND SAFETY OF ELRANATAMAB BY AGE AND FRAILTY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: A SUBGROUP ANALYSIS FROM MAGNETISMM-3
N Raje; X Leleu; A Lesokhin; M Mohty; A Nooka; E Leip; U Conte; A Viqueira; V Blunk; S Manier;
Hematol Transfus Cell Ther. 2023;45 Supl 4:S406-7
A PHASE 2 TRIAL OF ELRANATAMAB, A B-CELL MATURATION ANTIGEN (BCMA)-CD3 BISPECIFIC ANTIBODY, IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) MULTIPLE MYELOMA (MM): INITIAL SAFETY RESULTS FOR MAGNETISMM-3
AM Lesokhin; B Arnulf; R Niesvizky; M Mohty; NJ Bahlis; MH Tomasson; P Rodrguez-Otero; H Quach; NS Raje; S Iida; M Raab; A Czibere; S Sullivan; E Leip; A Viqueira; V Blunk; X Leleu;
Hematol Transfus Cell Ther. 2022;44 Supl 2:S245-6